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Renal cell carcinoma (RCC) is known to be resistant to chemo- and radiotherapy due to a high apoptotic threshold. Smac and XIAP
(X-linked inhibitor of apoptosis protein) proteins were detected in all RCC cell lines and tissue samples examined. We modulated the
function of XIAP, either through its constitutional downregulation with an shRNA vector or by applying a Smac-mimicking peptide.
Among RCC cell lines, Caki1 expresses the highest levels of XIAP. We transfected Caki1 with XIAP-targeting shRNA vector and
generated stable clones. XIAP was knocked down by RNA interference in clone no. 14 by 81.6% and in clone no. 19 by 85.3%.
Compared to the parental and mock-transfected cells, neither clone was more sensitive to conventional chemotherapeutic agents,
but both clones were more susceptible to Fas stimulation (Po0.0001) and to pharmacological Bcl-2 inhibition (Po0.0001), as well as
to a combination of the two (Po0.0001). Mature Smac binds to XIAP via the N-terminal residues, disrupting its interaction with
caspases and promoting their activity. We determined that exposure of Caki1 cells to Smac-N7 peptide (AVPIAQK) resulted in a
slight but significant decrease in viability (P¼0.0031) and potentiated cisplatin’s effect (P¼0.0027). In contrast with point targeting of
XIAP by shRNA, Smac-N7 peptide is active against several IAP (inhibitor of apoptosis protein) family members, which can explain its
role in sensitising cells to cisplatin. Our results suggest that multiple targeting of both Bcl-2 and XIAP or, alternatively, of several IAP
family members by the Smac-N7 peptide is a potent way to overcome resistance of RCC to apoptosis-triggering treatment
modalities, and might be a new tool for molecular targeted therapy.
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Being highly refractory to radio- and cytotoxic chemotherapy,
renal cell carcinoma (RCC) poses a significant problem for
conventional cancer treatment. Recently, molecular targeting
therapy employing multi-kinase inhibitors (MKIs) has raised hope
for patients with advanced RCC. Tyrosine kinase inhibitors such as
sorafenib and sunitinib (Motzer and Bukowski, 2006; Ljungberg
et al, 2007) are becoming first-line treatments for metastatic RCC.
However, as soon as resistance to MKIs develops, the patient
rapidly succumbs to the disease. It is now of utmost importance to
find ways to control cancer progression. Manipulation of the
apoptotic machinery is one promising approach.
Renal cell carcinoma expresses high levels of Bcl-2, which is one
of the early discovered and thoroughly studied inhibitors of
apoptosis. We have reported previously on the Bcl-2 status in RCC
(Tomita et al, 1996a) and discovered that the absence of Bcl-2
favours the response of RCC to immunotherapy (Maruyama et al,
2006).
XIAP (X-linked inhibitor of apoptosis protein) is the most
downstream inhibitor of apoptosis and is considered the most
potent and ubiquitous caspase inhibitor among the members of
the IAP (inhibitor of apoptosis protein) family. The translation
of XIAP is stimulated under different conditions of cellular stress
(Holcik et al, 1999) and overexpression of XIAP can be an
important event in cancer progression and resistance to treatment
(Holcik et al, 2000).
Members of the IAP family seem to be attractive targets for
anticancer therapy because tumour cells rely heavily on IAP
activity compared with normal cells (Yang et al, 2003a). XIAP
(Harlin et al, 2001), cIAP-1 (Conze et al, 2005), and cIAP-2 (Conte
et al, 2006) knockout mice are phenotypically normal. The
knockout phenotype can be revealed only under specific condi-
tions in some tissues and cells (Cummins et al, 2004; Conte et al,
2006; Zhao et al, 2007). Tumour cells have increased levels of
spontaneous apoptosis and intrinsic caspase activity (Yang et al,
2003a). By inhibiting XIAP, it is possible to kill tumour cells
without additional impact, as we demonstrated previously in
urothelial cancer (UC) (Bilim et al, 2003). Moreover, XIAP
antisense oligonucleotide chemosensitised UC to adriamycin. It
has also been shown that XIAP expression levels increased with the
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sprogression of RCC (Ramp et al, 2004; Yan et al, 2004; Mizutani
et al, 2007). In addition, an XIAP antisense oligonucleotide
sensitised RCC to Fas/TRAIL-induced apoptosis (Mizutani et al,
2007). Antisense oligonucleotides directed against XIAP sensitise
cancer cells to chemotherapeutic drugs in vitro (McManus et al,
2004) and those developed by Aegera Therapeutics Inc. are
currently being evaluated in phase I and II clinical trials
(Cummings et al, 2005; Schimmer et al, 2006).
There is a group of proteins phylogenetically conserved among
insects and mammals that are natural inhibitors of IAPs and that
share homology at the N terminus, which is critical to their
function. This active sequence binds to the BIR domain of IAPs,
disrupting interaction with both pro- and active caspases, thus
promoting their activation and function. The mammalian protein
Smac/DIABLO is encoded by a nuclear gene and translocated to
mitochondria, where its N-terminal mitochondrial targeting
sequence (MTS) is cleaved to reveal an active site (AVPIAQK).
It is released from mitochondria when the cell is exposed to
apoptotic stimuli and this release is antagonised by Bcl-2. Smac
expression is downregulated in RCC (Mizutani et al, 2005).
In vitro, peptides containing N-terminal residues of mature Smac/
DIABLO have been shown to promote apoptosis by blocking IAP
function.
However, there is still no strong evidence for efficacy of XIAP
downregulation as a potential approach to treating urological
malignancies. Here, we further analysed the functional significance
of XIAP in RCC cell lines, with special emphasis on the in vitro
targeting of XIAP by utilising recently invented technologies such
as RNA interference (RNAi) and the cell-permeable oligopeptide-
mimicking Smac N-terminal sequence.
MATERIALS AND METHODS
Immunohistochemistry
The study was approved by the Ethics Committee of Yamagata
University and all patients signed an informed consent form. The
surgical specimens from 34 consecutive patients who underwent
surgery (15 open, 19 laparoscopic; 26 radical nephrectomies,
8 nephron-sparing surgeries) for RCC from January to December
2005 at the Yamagata University Hospital were included in the
study. There were 22 males and 12 females, ranging in age from 28
to 80 (median, 62) years. Pathological staging was determined
according to the UICC TNM classification of malignant tumours.
Twenty-six tumours were postoperatively diagnosed as stage 1, 5
as stage 2, and 3 as stage 3a. Pathological grades were assigned
according to a system developed by the Japanese Urological
Association based on the degree of atypia of tumour cells. There
were 29 clear cell tumours, 2 chromophobes, and 3 papillary RCCs.
Monoclonal mouse antibodies for XIAP (clone 48) and Smac/
DIABLO (clone 7) (BD Transduction Laboratories, San Diego, CA,
USA) were used. Two 5-mm-thick paraffin sections from different
parts of each tumour representative of the entire tumour were
used. Epitops were reactivated by autoclaving sections in 10mM
citric buffer (pH 6.0) for 10min. Bound primary antibody was
detected by the peroxidase method using the Histofine simple stain
MAX-PO (Nichirei, Tokyo, Japan). The staining reaction was
developed by DAB and nuclear counterstaining was performed
with haematoxylin. Positive and negative controls were included
in each staining series. Adjacent normal kidney served as an
internal positive control in selected sections.
The intensity of XIAP staining, established previously by Ramp
et al (2004), was determined for both XIAP and Smac. The
intensity was scored as follows: 0, no staining; 3, strong staining
comparable with that of convoluted tubule epithelial cells of
normal kidney; and 1 and 2, weak and moderate staining,
respectively, that is, intermediate between the former two. The
proportion of stained cells expressed as a percentage multiplied by
the intensity index produced the staining score. Two different
sections from each tumour were examined by immunohistochem-
istry (IHC), and the mean score for each patient was included in
the statistical analysis.
Cell culture
Established renal cell cancer cell lines ACHN, KRC/Y, Caki1, Caki2,
A704, and A498 were obtained from ATCC (Rockville, MD, USA)
and cultured as described previously (Tomita et al, 1996b). The
small-molecule Bcl-2 inhibitor HA14-1 was purchased from
Calbiochem (San Diego, CA, USA), CH11 was from MBL (Nagoya,
Japan), cisplatin was from Nippon Kayaku (Tokyo, Japan), and
docetaxel was from Sigma-Aldrich Japan (Tokyo, Japan).
RT–PCR
Total RNA from RCC cell lines was isolated using the SV Total
RNA Isolation System (Promega, Madison, WI, USA). The
integrity of the extracted RNA was confirmed by gel electropho-
resis. Two micrograms of total RNA was subjected to RT–PCR
using a first-strand cDNA synthesis kit (Roche Molecular
Biochemicals, Indianapolis, IN, USA) and AmpliTaqt (Perkin
Elmer, Branchburg, NJ, USA), as described elsewhere. To ensure
appropriate first-strand cDNA synthesis, the b-actin gene RT–PCR
was performed as described by Raff et al (1997). Bcl-2 family
members were amplified using an ApoPrimer Set (Takara Bio,
Shiga, Japan) according to the manufacturer’s instructions. IAP
family primers were according to Ka and Hunt (2003).
Immunoblotting
Immunoblotting was performed as described previously (Tomita
et al, 1996b). Horseradish peroxidase-labelled secondary antibody
was detected using a SuperSignal West Pico Substrate (Pierce,
Rockford, IL, USA) according to the manufacturer’s instructions.
b-Actin was used as a loading control. The images were analysed
using UN-SCAN-Itgel Automated Digitizing System software
(version 5.1 for Windows, Silk Scientific Inc., Orem, UT, USA).
The following antibodies were used: anti-Bcl-2 (clone 124) from
DAKO (Tokyo, Japan); polyclonal anti-c-IAP1 (no. 4952), anti-
caspase 3 (no. 9662), and anti-survivin (no. 2802) from Cell
Signaling Technology (Danvers, MA, USA); anti-PARP (clone 7D3-
6), anti-XIAP (clone 28), anti-Smac (clone 7), anti-caspase 3 (clone
19), anti-Bcl-x (clone 44), anti-Beclin (clone 20), anti-Bad (clone
48), anti-Bax (clone 3), and anti-c-IAP2 (clone F30-2285) from BD
(Franklin Lakes, NJ, USA); and anti-b-actin from Abcam Inc.
(Cambridge, MA, USA).
RNAi
Three XIAP-targeting short hairpin RNA vectors were generated
using pcPURU6beta-i-cassete with the target sequences 50-GTAGA
AGAGTTTAATAGAT-30 (TA0025-1), 50-GCCGGAATCTTAATATT
CG-30 (TA0025-2), and 50-AGGTGAAGGTGATAAAGTA-30 (TA0025-
4) by Takara Bio. Transfection was carried out using TransIT-
LT1
s transfection reagent (Mirus Bio Corporation, Madison, WI,
USA). In preliminary experiments, TA0025-4 demonstrated the
highest ability to suppress XIAP and was selected for further
experiments. For generation of stable transfectant clones, the
transfected cells were selected with puromycin for 3–4 weeks.
Twenty selected clones were screened for XIAP expression, and
clone nos. 14 and 19 with the lowest levels of XIAP (20.6 and 14%
of the control level, respectively) were selected for further
experiments. We also isolated puromycin-resistant mock transfec-
tants, produced by transfection of the vector carrying irrelevant
sequence (50-CACCTTTTTTT-30) with no mammalian homology.
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sPeptide transfection
The N-terminal residues of mature Smac/DIABLO are critical to its
function. Smac-N7 peptide (AVPIAQK) and a functionally inactive
control peptide (MVPIAQK) were synthesised by Sigma-Aldrich
Japan. To deliver the peptides to cultured cells, the following two
transfection reagents were used: Chariot (Active Motif, Tokyo,
Japan) and BioPORTER (Sigma-Aldrich). The cell-permeable
peptide Smac-N7 (AVPIAQK-PRQIKIWFQNRRMKWKK) bound
to an antenopedia sequence facilitating incorporation into the cells
was from Calbiochem.
Measurement of cell viability and cell proliferation
Cell viability was detected with a colorimetric assay, the CellTiter
96
s AQueous One Solution Cell Proliferation Assay (Promega),
utilising tetrazolium compound according to the manufacturer’s
instructions. Each dose was examined in four or six wells of a 96-
well plate (BD Falcon, Franklin Lakes, NJ, USA). Each experiment
was repeated at least three times and representative results are
presented. For estimation of cell proliferation, BrdU cell prolifera-
tion assay (Calbiochem) was carried out according to the
manufacturer’s instructions. The experiment was repeated twice
in quadruplicate.
Detection of apoptosis
Cells were cultured in Lab-Tek Chambers (Nunc Inc., Naperville,
IL, USA) and treated with the peptide or cisplatin as described
above. Apoptotic morphological changes were detected with
Giemsa (Sigma-Aldrich) (3% in 15mM phosphate buffer pH 6.8)
and Hoechst 33342 (Dojindo Laboratories, Kumamoto, Japan)
staining followed by observation under light and fluorescence
microscopes, respectively. For the detection of early apoptosis,
cells were stained with the Annexin V FITC Apoptosis Detection
Kit I (BD) according to the manufacturer’s instructions. Propidium
iodide (PI) staining of the fixed cells, as described elsewhere, was
carried out for quantification of late apoptotic events. Stained cells
were analysed on FACSCaliburt Flow Cytometer (BD).
Statistical analysis
Continuous variables are presented as mean±s.d. Except for IHC
scores, which were considered nonparametric and analysed using
AB
CD
30 m 30 m
30 m 30 m
Figure 1 Immunohistochemical examination of Smac (A, C) and XIAP (B, D) in normal kidney (A, B) and RCC (C, D). In normal kidney, Smac
expression was detected in tubular epithelial cells, Bowman capsule cells, and a portion of glomerular cells (A). In tumours, Smac staining was weaker than in
normal kidney (C). XIAP expression was restricted to tubular epithelial and several glomerular cells in normal kidney (B).
46 kDa Actin
23 kDa Smac
Normal Normal Tumour Tumour
RT127 RT133
46 kDa -Actin
57 kDa XIAP
23 kDa Smac
ACHN
KRC/Y
Caki1
Caki2
A704
A498
Figure 2 Western blot analysis of XIAP and Smac expression in paired
tissue samples from normal kidney and RCC (A). Smac levels were lower
in RCC than in normal kidney. Expression of XIAP and Smac in a panel of
RCC cell lines (B). Both molecules were ubiquitously expressed, with the
highest levels of XIAP in Caki1 cells. b-Actin was used as a control for
loading.
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sthe Kruskal–Wallis test, all other continuous variables in the
present study met the criteria for a normal distribution and were
assumed to be parametric. They were analysed using a two-tailed
t-test or one-way ANOVA where appropriate. In cases where the
groups were ordered and equally spaced (as the data presented in
Figure 6), the post-test for a linear trend was performed; otherwise,
a Tukey post-test to compare all pairs of values was used (as the
data presented in Figure 5A and B). P-values lower than 0.05 were
considered statistically significant. Analysis was performed using
GraphPad Prism version 3.02 for Windows (GraphPad Software
Inc., San Diego, CA, USA).
RESULTS
XIAP and Smac expression in tissue samples and cell lines
By IHC, XIAP expression was found to be restricted to tubular
epithelial and several glomerular cells, and Smac expression was
detected in tubular epithelial cells, Bowman capsule cells, a portion
of glomerular cells, and fibroblasts in normal kidney (Figure 1).
In tumourous tissues, Smac was found in all tumours, with staining
scores ranging from 200 to 300 and staining intensity weaker than
in normal kidneys. Smac expression did not vary between different
tumour stages and grades. XIAP expression levels increased from
pT1 (164.423±108.170) to pT2 (195.000±83.367) and pT3
(266.667±57.735), as well as from grade 1 (75.000±98.742) to
grade 2 (201.250±93.695) (Po0.05). However, in grade 3, the
staining score decreased slightly (173.333±110.151). The chromo-
phobe histological subtype presented with a higher staining score
(275.000±35.355) than the clear cell type (171.724±107.614) or
papillary type (173.333±75.056), but the difference was not
significant.
The presence of both proteins was confirmed by western
blotting of selected pairs of normal–tumour tissue samples
(Figure 2A; data not shown) and Smac levels were lower in
tumour tissues than in paired normal kidneys. XIAP protein was
detected in all RCC cell lines examined and the expression differed
slightly among the cells, with the highest level in Caki1 cells
(Figure 2B). A Smac-specific band was also detected in all cell lines,
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Figure 3 Western blot analysis of XIAP in Caki1 cells transfected with an XIAP-targeting shRNA vector (A). Figures above the panel indicate normalised
expression (%). Clone nos. 14 and 19 with the lowest levels of XIAP were selected for further experiments. The relative viability (MTS assay) of Caki1
parental cells, mock-transfected cells, and clone nos. 14 and 19 treated with the indicated doses of adriamycin, mitomycin C, cisplatin, and docetaxel for 24h
is shown (B).
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swith the highest level of expression in KRC/Y and the lowest in
A498 (Figure 2B).
XIAP shRNA stable clones
To explore the effect of a constitutional decrease in XIAP on cell
survival and susceptibility to apoptosis, we generated stable Caki1
clones of shRNA expressing vector targeting XIAP (TA0025-4) as
well as a control vector as described in Materials and Methods. In
the two clones selected for further experiments, XIAP protein was
suppressed by 79.4% in clone no. 14 and by 86% in clone no. 19
(Figure 3A). The stable transfectants and mock clone did not
demonstrate any morphological difference from the parental cells.
We studied sensitivity of the cells to conventional anticancer
drugs, which are considered to exert their effect through induction
of apoptosis and are widely used in urology to treat bladder,
testicular, and prostate cancer. Unexpectedly, all the cells,
including parental cells and mock clones, showed equal sensitivity
to adriamycin, mitomycin C, cisplatin, and docetaxel (Figure 3B).
As there is redundancy in the IAP family and other members can
be reciprocally upregulated to substitute for XIAP, we performed
RT–PCR and western blotting for apoptosis-related genes. The
messengers of Bcl-2 and IAP family members examined were
present and did not show drastic changes among the parental cells,
mock transfectants, and clone nos. 14 and 19 (Figure 4A).
Furthermore, to check for protein levels, we performed western
blot analysis. The levels of Bcl-2 family members were unchanged
but those of c-IAP1 and c-IAP2 (Figure 4B) increased slightly in
mock cells and transfectants. This was not a specific modulation
due to downregulation of XIAP, as it was also observed in mock
cells. Rather, it can be explained by the effect of cellular stress due
to transfection and selection process. The knockdown of XIAP by
RNAi sensitised the cells to HA14-1, a small-molecule Bcl-2
inhibitor (Figure 5A), but this effect was moderate and observed
only at a single concentration of HA14-1 (25mgml
 1). At this dose,
the overall P-value was less than 0.0001. P-values between each
pair of the cells calculated with the post-test are presented in
Figure 5A. As XIAP inhibition sensitised chronic lymphocytic
leukaemia cells (Kater et al, 2005) and RCC cells (Mizutani et al,
2007) to Fas-induced apoptosis, we treated the parental cells, mock
transfectants, and clone nos. 14 and 19 with CH11 IgM Fas-
stimulating monoclonal antibody (Figure 5B). Overall, the viability
of clone nos. 14 and 19 was significantly lower than that of the
parental cells or mock transfectants (Po0.0001). P-values between
each pair of the cells calculated with the post-tests are presented in
Figure 5B. Double treatment with CH11 and HA14-1 resulted in
a significant (Po0.0001) decrease in the viability of clone nos. 14
and 19 (Figure 5B), and a synergistic effect of the two compounds
was observed in parental cells, mock transfectants, and clone no.
19. As the decrease in relative viability can be attributed to
decreased cell proliferation, nonspecific toxicity, and non-apopto-
tic cell death, we performed additional experiments to clear this
Bcl-2 family members
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Figure 4 RT–PCR analysis (A) and western blot analysis (B) for Bcl-2 and IAP family members in the Caki1 parental cells, mock-transfected cells, and
clone nos. 14 and 19. b-Actin was used as a control for loading. The messengers of all examined genes were present in the cells and remained unchanged.
Apoptosis-related proteins were also not changed except cIAP-1 and cIAP-2, which were slightly increased in mock transfectants and clone nos. 14 and 19,
which presumably reflects the effect of cellular stress during transfection and selection process.
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spoint. There was no difference in BrdU incorporation, which is a
marker of cell proliferation, between untreated and treated cells
(data not shown). The proportion of annexin V-positive cells,
which is an early apoptosis marker, increased in double-treated
cells from 5.0% (parental) and 3.05% (mock no. 5) to 6.03% (clone
no. 14) and 9.41% (clone no. 19). Furthermore, there was a drastic
increase in sub-G1 population after PI staining in clone nos. 14
(21.59%) and 19 (29.73%) compared to parental (8.01%) and mock
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Figure 5 Relative viability (MTS assay) of Caki1 parental cells, mock-transfected cells, and clone nos. 14 and 19 treated with the small-molecule Bcl-2
inhibitor HA14-1 for 24h (A). The same cells treated with either CH11 (500ngml
 1) Fas-stimulating antibody or a combination of CH11 (500ngml
 1) and
HA14-1 (25mgml
 1) for 24h (B). One-way ANOVA with a Tukey post-test to compare all pairs of values was used. (C) Cells untreated (left column) or
treated with a combination of CH11 (500ngml
 1) and HA14-1 (25mgml
 1) for 24h (right column) were fixed and stained with PI and further analysed on
a flow cytometer to detect sub-G1 population – a late apoptotic event. Figures indicate percentage of cells of sub-G1 population. A drastic increase in sub-
G1 population was observed in clone nos. 14 and 19. (D) Western blot of untreated control cells (C) or cells treated with a combination of CH11
(500ngml
 1) and HA14-1 (25mgml
 1) for 24h (T). Membranes were probed with anti-caspase 3 or anti-PARP antibody. The upper panel presents
caspase-3 blot after normal exposure showing a decrease in zymogen caspase 3 in clone nos. 14 and 19, and the lower panel shows overexposed blot with
clearly observed caspase-3-cleaved fragments in clone nos. 14 and 19 after double treatment. PARP cleavage was also observed, indicating activation
of biochemical apoptotic pathways. b-Actin was used as a control for loading.
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stransfectants (12.12%) (Figure 5C). This was accompanied with
PARP and caspase-3 cleavage (Figure 5D, the upper panel presents
caspase-3 blot after normal exposure demonstrating consumption
of the proform of the protein and the lower panel shows
overexposed blot with clearly observed caspase-3-cleaved frag-
ments in clone nos. 14 and 19 after double treatment), indicating
activation of biochemical apoptotic pathways. These data confirm
the hypothesis that the decrease in viability of clone nos. 14 and 19
was due to acceleration of apoptosis.
Smac-mimicking peptide
Transfection of the ACHN and Caki1 cells with Smac-N7 or control
peptide using either Chariot or BioPORTER protein transfection
reagent resulted in pronounced nonspecific cytotoxicity. We
switched from unbound peptide to antenopedia-linked peptide,
which can be delivered to the cells without additional transfection
reagent. Treatment of Caki1 cells with various doses of the
antenopedia-bound Smac-mimicking peptide resulted in a sig-
nificant dose-dependent decrease in viability (overall P¼0.0031;
linear trend Po0.0001, r
2¼0.804) (Figure 6A) and a further effect
in combination with cisplatin was observed (overall P¼0.0027;
linear trend Po0.0001, r
2¼0.8419) (Figure 6A). The time course
demonstrated increased toxicity with time in the case of the
peptide alone and also in combination with cisplatin (linear trend
Po0.0001, r
2¼0.2892 and Po0.0001, r
2¼0.842, respectively)
(Figure 6B). Addition of the Smac-mimicking peptide to the
medium containing cisplatin accelerated apoptosis, as typical
morphological changes were observed (Figure 7A and B).
DISCUSSION
The present immunohistochemical data are consistent with
previous reports that XIAP expression was increased in RCC
compared with normal kidney and XIAP levels (Ramp et al, 2004;
Yan et al, 2004; Mizutani et al, 2007) correlated with tumour
progression. Despite several previous attempts, there is still no
consensus on the significance of Smac to the malignant potential of
RCC (Yan et al, 2004; Mizutani et al, 2005). Here, we found that
Smac levels were lower in RCC than in normal kidney; however,
the levels were similar in various tumour tissues. In our limited
series, the distribution is skewed in favour of low-stage (26 (76.5%)
were stage 1) and low-grade (90% were grade 1–2) tumours.
Previously, we demonstrated the importance of XIAP to the
malignant potential of transitional cell cancer (TCC) and the
chemosensitisation of TCC by XIAP antisense oligonucleotides
(Bilim et al, 2003). A decrease in the levels of XIAP has been
reported to sensitise cancer cells to cytotoxic T lymphocytes
(Kashkar et al, 2006), radiation (Ohnishi et al, 2006), and
anticancer drugs (Hu et al, 2003). XIAP antisense oligonucleotides
potentiated Fas/TRAIL-induced apoptosis in RCC (Mizutani et al,
2007). To our knowledge, RNAi technology has not been used
previously to downregulate the expression of XIAP in RCC cells
and there are no reports on the functional significance of XIAP in
RCC. Here, XIAP downregulation did not sensitise RCC cells to
cisplatin, docetaxel, adriamycin, or mitomycin C. There are several
putative explanations for this phenomenon. One is the absence of
caspases. However, as demonstrated previously, caspase expres-
sion was preserved in RCC from patients and cell lines (Gerhard
et al, 2003), and caspase 3 was detected in Caki1 cells (Figure 5D).
On the other hand, the redundancy of IAP family members or the
importance of high Bcl-2 levels cannot be ruled out.
Renal cell carcinoma expresses high levels of Bcl-2 expression
without gene amplification, as demonstrated previously by us
(Tomita et al, 1996a). This fact can explain RCC’s high resistance
to conventional chemo- and radiotherapy, and the absence of Bcl-2
had a positive predictive value for the response to immunotherapy
in metastatic RCC, as was disclosed in our recent study (Maruyama
et al, 2006). Proapoptotic Bcl-2 family members Bid, Bak, and Bax
are essential for the release of cytochrome c and Smac from
mitochondria (Kandasamy et al, 2003), whereas Bcl-2 and Bcl-xL
prevent mitochondrial release of Smac (Sun et al, 2002). The
downregulation of Bcl-2 expression by antisense PODN resulted in
Smac’s translocation to the cytoplasm in T24 UC cells (our own
unpublished observation). High levels of Bcl-2 can explain the
inability of downregulation of XIAP expression to sensitise RCC
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Figure 6 Relative viability (MTS assay) of Caki1 cells treated with
indicated concentrations of Smac-Ant peptide (AVPIAQK) alone or in
combination with cisplatin (50mgml
 1) for 24h (A). The cells were
exposed to 200mM Smac-Ant peptide (AVPIAQK), cisplatin (50mgml
 1),
or a combination of the two agents for 24, 48, and 72h (B). One-way
ANOVA with post-test for linear trend was used to analyse the data.
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scells to chemotherapeutic drugs, which are believed to trigger an
intrinsic, mitochondria-mediated apoptotic pathway. It is feasible
that proapoptotic signalling is blocked by Bcl-2 at the level of
mitochondria, upstream of XIAP. In this light, the sensitisation to
Fas-induced apoptosis caused by the knockdown of XIAP
(Figure 5B) is easy to understand, as ligands to TNF family
receptors can directly activate downstream caspases bypassing
mitochondria. We tried targeting Bcl-2 with a small-molecule
inhibitor that induced cell death more efficiently (Po0.0001;
Figure 5A) in XIAP-knockdown cells compared to parental cells or
mock transfectants. The engagement of Fas receptors with
simultaneous targeting of Bcl-2 resulted in a significant
(Po0.0001) decrease in viability of clone nos. 14 and 19
(Figure 5B) and a synergistic effect was observed in parental cells,
mock transfectants, and clone no. 19.
The decrease in cellular viability due to the combination of
CH11 and small-molecule Bcl-2 inhibitor was a result of enhanced
apoptosis. The presence of annexin V-positive cells and the drastic
increase in sub-G1 population (Figure 5C) confirm this statement.
Apoptosis was easily induced in clone nos. 14 and 19, compared
with parental and mock cells. This is in agreement with the results
of viability assay. The cleaved product of caspase 3 was observed
only in clone nos. 14 and 19, but not in parental or mock
transfectants, and PARP cleavage was most prominent in the cells
with XIAP knockdown (Figure 5D). Thus, combined targeting of
XIAP with Bcl-2, which blocks apoptotic signalling at the
mitochondrial level and downstream of it, with simultaneous
stimulation of Fas facilitates apoptosis in RCC.
Redundancy of IAP family members is another possibility. It is
known that Smac peptide acts not only on XIAP but also on other
IAP family members: melanoma IAP, survivin, cIAP1, and cIAP2,
the last three being expressed in RCC and their expression
confirmed in Caki1 cells (Figure 4A). Various approaches are
being used to develop Smac-mimicking reagents for inhibiting
XIAP. One approach is to design small molecules. Another is to use
N-terminal Smac peptides. Smac peptide enhanced the apoptosis
induced by chemotherapeutic drugs (Arnt et al, 2002; Yang et al,
2003b) or TRAIL (Guo et al, 2002). Thus, Smac-N7 peptide
efficiently sensitised the cells to cisplatin (Figures 6 and 7), which
was not achieved by only targeting XIAP.
Consequently, to overcome the resistance of RCC cells to
apoptosis, a combination of treatments targeting several molecules
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Figure 7 Phase contrast (left), Hoechst 33342 (middle), and Giemsa (right) photographs of Caki1 cells treated with 200mM Smac-Ant peptide, 50mgml
 1
cisplatin, or a combination of the two agents for 24h (A). (B) Higher magnification of phase contrast (upper panel) and Hoechst 33342 (lower panel)
photographs of the same field of Caki1 cells treated with a combination of Smac-Ant peptide (AVPIAQK) (200mM) and cisplatin (50mgml
 1). Cells undergo
typical apoptotic morphological changes (condensed fragmented nuclei with formation of apoptotic bodies) as indicated by arrows.
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sis necessary. The engagement of a TNF receptor-mediated pathway
simultaneously with the downregulation of XIAP expression with
or without the targeting of Bcl-2 is promising. Alternatively,
targeting several IAP family members with Smac-N7 peptide in
combination with conventional chemotherapy can be done. The
main problem with applying these approaches to the clinical
setting is the absence of a suitable drug delivery system for nucleic
acids (siRNAs or antisense oligonucleotides) and peptides. In this
light, the creation of small molecular targeting drugs seems to be
more appropriate, with the application of RNAi and peptides to
search for promising molecular targets.
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